J.W. Cole Advisors Inc. Acquires 6,301 Shares of Eli Lilly and Company $LLY

J.W. Cole Advisors Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 33.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 25,109 shares of the company’s stock after acquiring an additional 6,301 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Eli Lilly and Company were worth $19,573,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Braun Bostich & Associates Inc. lifted its position in Eli Lilly and Company by 2.5% during the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after purchasing an additional 13 shares during the last quarter. Rise Advisors LLC increased its holdings in shares of Eli Lilly and Company by 1.8% in the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock worth $571,000 after buying an additional 13 shares during the last quarter. Occidental Asset Management LLC raised its position in shares of Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after buying an additional 13 shares in the last quarter. New Insight Wealth Advisors raised its position in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock valued at $307,000 after buying an additional 13 shares in the last quarter. Finally, Dash Acquisitions Inc. lifted its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.8%

LLY opened at $1,067.68 on Tuesday. The company has a market cap of $1.01 trillion, a P/E ratio of 69.78, a P/E/G ratio of 1.21 and a beta of 0.43. The business’s 50-day moving average price is $862.28 and its 200-day moving average price is $790.04. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,075.72.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the business posted $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their target price for the company from $886.00 to $1,104.00 in a research note on Monday, November 10th. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a report on Monday, November 10th. HSBC increased their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. CICC Research boosted their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Finally, BMO Capital Markets upped their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,047.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.